In Finland they made a dance to show migrants not to rape them "Stop don't touch me, this is my no go space"

🔥🚨DEVELOPING: George Soros is going viral after GEO Politics Prime released this compilation exposing him for being one of the biggest puppet masters alive. Interviewer: You’re the guy they said broke the England Bank George Soros: “Well, that’s true.”

The truth is that there are VASTLY more hate crimes, especially aggravated rape and murder, per person by Blacks against Whites than the other way around. The is not remotely debatable, as the numbers are so extremely lopsided!

Why are healthy young people suddenly developing aggressive cancers? The sudden rise of aggressive cancers in young people isn’t a coincidence—it’s a crisis. From turbo cancers to unprecedented diagnoses in children, the medical community needs to answer the hard questions about gene therapy and toxic injectables. I refuse to stay silent.

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊

This is one of the men that attacked me in NYC. Police are still searching for him. Please share this photo. Violence ends conversations; free speech begins them. Violence deserves accountability.

RT @PeriklesGREAT: Why all the black on white violence ? Black on white violence is 41 times higher than white on black adjusted for popul…

$KODK #Kodak #eastmankodak #VoteNoKODK #VoteAgainstContinenza #KODKProxy CHANGE YOUR VOTE BEFORE THE ANNUAL MEETING, MAY 20. URGENT!! Kodak CEO James Continenza explicitly dismissed checking or caring about the company’s share price in a media interview. CNBC "He explained that Kodak's stock is "supposed to crawl, because that's how we grow," instead of experiencing volatile spikes." "Disregard for stock price: He explicitly said, "I don't look at our stock price. I don't care. I couldn't tell you what it is today." Problems- No color on Quarterly Calls. Reads a statement like a 4th grader doing a book report. No forward statements. No analyst questions. Attends ZERO analyst roundtables. SHOULD NOT BE BOTH CEO AND COB! Stock has dropped after every quarterly call this clown show does! Furthermore, Fat Jim has his friends from Vivial, a tiny 23-million-dollar company. No Chemical, print or cGMP pharma experience! These individuals joined Kodak around or after Continenza’s increased involvement (board in 2013, Executive Chairman in 2019, CEO in 2020), consistent with him bringing over trusted operators from his telecom/marketing/tech turnaround experience. Here are the documented cases from Kodak’s official executive leadership bios: From VIVIAL Jim Barnes (Chief IT Implementation Officer, joined Kodak in 2021, reports to Continenza): Previously Chief Information and Technology Officer at Vivial, Inc. for six years. Long career in IT/transformation projects (including at CSC), but the direct prior role was at Continenza’s Vivial. kodak.com Denisse Goldbarg (CMO and Head of EAMER Sales): Previously Chief Marketing Officer at Vivial, Inc. (responsible for corporate marketing strategy) and Global Chief Operating Officer at mGage (a Vivial group company, overseeing worldwide sales/operations/marketing). Earlier in her career, she was VP Marketing at Teligent (another Continenza leadership role) as well as at Time Warner Cable, MCI, etc. kodak.com Jim Moran (Chief Administration Officer and President of Eastman Business Park, reports to Continenza): Previously Chief Operating Officer at Vivial Media (oversaw sales, operations, legal, and real estate). Also held sales/operational roles at STi Prepaid, Teligent, and Lucent—directly aligning with Continenza’s prior executive positions at those companies. kodak.com But hey, crawling $KODK growth with these resumes is his goal

$KODK #Kodak #eastmankodak #VoteNoKODK #VoteAgainstContinenza #KODKProxy CHANGE YOUR VOTE BEFORE THE ANNUAL MEETING, MAY 20. URGENT!! Kodak CEO James Continenza explicitly dismissed checking or caring about the company’s share price in a media interview. CNBC "He explained that Kodak's stock is "supposed to crawl, because that's how we grow," instead of experiencing volatile spikes." "Disregard for stock price: He explicitly said, "I don't look at our stock price. I don't care. I couldn't tell you what it is today." Problems- No color on Quarterly Calls. Reads a statement like a 4th grader doing a book report. No forward statements. No analyst questions. Attends ZERO analyst roundtables. SHOULD NOT BE BOTH CEO AND COB! Stock has dropped after every quarterly call this clown show does!

$KODK #VoteNoKODK #VoteAgainstContinenza #KODKProxy CHANGE YOUR VOTE BEFORE THE ANNUAL MEETING MAY 20 IS URGENT!! Kodak CEO James Continenza explicitly dismissed checking or caring about the company’s share price in a media interview. CNBC "He explained that Kodak's stock is "supposed to crawl, because that's how we grow," instead of experiencing volatile spikes." "Disregard for stock price: He explicitly said, "I don't look at our stock price. I don't care. I couldn't tell you what it is today." Problems- No color on Quarterly Calls. Reads a statement like a 4th grader doing a book report. No forward statements. No analyst questions. Attends ZERO analyst roundtables. SHOULD NOT BE BOTH CEO AND COB! Stock has dropped after every quarterly call this clown show does!

Time to replace him with someone who actually wants to build something instead of just extending his own runway. Kodak deserves better than this perpetual underachiever in the corner office. His compensation is way outsized for the market cap and his performance. The stock is down 30% in one week! He is a pernicious, destructive force. Did James Continenza disregard the share price of Kodak in an interview? (CNBC) should have been fired immediately. Shareholder value is not his concern, as clearly demonstrated. Yes, Kodak CEO James Continenza explicitly dismissed checking or caring about the company’s share price in a media interview. CNBC "He explained that Kodak's stock is "supposed to crawl, because that's how we grow," instead of experiencing volatile spikes." "Disregard for stock price: He explicitly said, "I don't look at our stock price. I don't care. I couldn't tell you what it is today." Problems- No color on Quarterly Calls. Reads a statement like a 4th grader doing a book report. No forward statements. No analyst questions. Attends ZERO analyst roundtables. SHOULD NOT BE BOTH CEO AND COB! Stock has dropped after every quarterly call this clown show does! #DimensionalFundAdvisors #GeodeCapital #InstitutionalInvestors #gmtcapital #Vanguard $KODK #jimcontinenza #eastmankodak #bgolisano #Kodak #grandoakscapital #JamesVContinenza #PhilippeDKATZ #jasonnew #darrenlrichman #michaelesileck #davidpbovenzi #jeffreyengelberg #georgekarfunkel #williamparrett #davidebullwinkle

#DimensionalFundAdvisors #GeodeCapital #InstitutionalInvestors #gmtcapital #Vanguard $KODK #jimcontinenza #eastmankodak #bgolisano #Kodak #grandoakscapital #JamesVContinenza #PhilippeDKATZ #jasonnew #darrenlrichman #michaelesileck #davidpbovenzi #jeffreyengelberg #georgekarfunkel #williamparrett #davidebullwinkle x.com/IcnpcS/status/20542174… Time to replace him with someone who actually wants to build something instead of just extending his own runway. Kodak deserves better than this perpetual underachiever in the corner office. His compensation is way outsized for the market cap and his performance. The stock is down 30% in one week! He is a pernicious, destructive force. Did James Continenza disregard the share price of Kodak in an interview? (CNBC) should have been fired immediately. Shareholder value is not his concern, as clearly demonstrated. Yes, Kodak CEO James Continenza explicitly dismissed checking or caring about the company’s share price in a media interview. CNBC "He explained that Kodak's stock is "supposed to crawl, because that's how we grow," instead of experiencing volatile spikes." "Disregard for stock price: He explicitly said, "I don't look at our stock price. I don't care. I couldn't tell you what it is today." Problems- No color on Quarterly Calls. Reads a statement like a 4th grader doing a book report. No forward statements. No analyst questions. Attends ZERO analyst roundtables. SHOULD NOT BE BOTH CEO AND COB! Stock has dropped after every quarterly call this clown show does!

$kodk #jimcontinenza #eastmankodak #bgolisano #Kodak #grandoakscapital Time to replace him with someone who actually wants to build something instead of just extending his own runway. Kodak deserves better than this perpetual underachiever in the corner office

It was a coup.

$KODK #Eastmankodak @tomgolisano #davidpbovenzi #grandoakscapital #tomgolisano #grandoakscapital #eastmankodak $KODK it is far past time for division of #jimcontinenza duties of both roles of CEO and Chairman. He has no oversight. He needs to go NOW! A different CEO with #pharmaceutical or #chemicals experience and expertise is needed NOW. No one respects this leadership!! His moderation of earnings calls is indicative of micromanaging and a pernicious narcissist lacking character depth.

The Hedges are giving you a GIFT in $KODK - they just had earnings and as usual the VOLATILITY is HIGH - Gross profit: $57 million ( $11M or 24%), with gross margin expanding to 22% (from 19%). - Operational EBITDA: $15 million (vs. $2M; $13M). This marks the third consecutive quarter of year-over-year growth in revenue, gross profit, and Operational EBITDA. SO OF COURSE THEY TAKE IT DOWN AFTER HOURS - SEE HOW THE GAME WORKS trade-ideas.com/share.php?co…

.@realDonaldTrump - LOOK AT $KODK - THE SHORTS are HUNTING IT! THIS IS WHAT THEY DO! - $KODK what happens when THE NEWS BREAKS that $KODK is doing the Watermark non counterfeit BALLOTS for ALL ELECTIONS - THEY WON'T BE ABLE TO BUY IT BACK - THE the WHOLE MARKET IS IN DANGER! SHORTING MUST BE STOPPED! trade-ideas.com/share.php?co…

$KODK is going to be making the sophisticated Watermark Paper - I am long this BIGLY and if you are NOT - You hate winning! Do you REALLY NOT GET IT YET? kodak.com/en/advanced-materi…

This is the single greatest political ad I have ever seen.

The FDA knew the COVID shots would kill and maim countless Americans. They kept injecting anyway. One government employee tried to sound the alarm about “49 examples” of deadly side effects that conventional safety analyses weren’t detecting. She was shut down. Her name was Dr. Ana Szarfman. On March 1, 2021, less than three months after the rollout of the COVID-19 injections, Dr. Ana Szarfman, an employee at CDER and safety data mining developer, warned that the FDA’s existing system could hide vaccine safety signals due to a flaw called “masking.” She proposed a newer method developed by statistician Dr. William DuMouchel that corrected for this issue and, when applied, detected “49 examples of extreme masking” that the standard system did not. These “49 examples of extreme masking” include not “minor” but serious adverse events: • Bell’s palsy • Cardiac failure • Acute left ventricular failure • Agonal rhythm (severe end-of-life arrhythmia) • Pulmonary infarction • Cerebral artery occlusion • Aortic stenosis • Sudden cardiac death • Hypertensive emergency • Basal ganglia stroke When Dr. Szarfman proposed a new method, she was told to “hold off on creating and sending data mining reports and analyses.” Later, they “made it clear” that she “needs to focus on her assigned work” and “should not be discussing or providing internal analyses externally.” As Dr. Szarfman puts it, her work became a “pest” for raising concerns about safety signal masking. In September 2021, Dr. Peter Marks, the FDA's top vaccine official, decided that Dr. Szarfman’s COVID vaccine data-mining days were over. He informed Dr. Patrizia Cavazzoni, the then director of CDER, that Dr. Szarfman “has been asked to cease and desist conducting her data analysis.” Dr. Marks complained that Dr. Szarfman’s work had become “a major distraction” and that her efforts could “create erroneous conflicts that feed into anti-vaccination rhetoric.” Dr. Szarfman went on to retire from the FDA in 2025 after more than 35 years of service. She raised concerns about safety signal masking. The FDA essentially told her to shut up. Because in their eyes, “49 examples of extreme masking” could create “erroneous conflicts” and fuel “vaccine hesitancy.” Unfortunately, this is not a one-off instance. It’s part of a much deeper problem: the gap between what’s known internally and what’s allowed to reach the public. 🧵